📖 Полное руководство Обновлено 2026🔬 На основе доказательств

Руководство по Тесаморелину

Дозировка Egrifta, снижение жира и протокол

Полное руководство по Тесаморелину (Egrifta): одобренный FDA аналог GHRH для борьбы с висцеральным жиром.

Egrifta: Одобренный FDA аналог GHRH

Тесаморелин (бренд Egrifta) — это модифицированный аналог GHRH, который стимулирует выброс гормона роста с превосходной стабильностью. В клинических испытаниях он показал снижение висцерального жира на 15–20%.

Механизм и ключевые эффекты

Tesamorelin is a synthetic analog of endogenous GHRH (growth hormone-releasing hormone) with a trans-3-hexenoic acid chemical modification at the N-terminus. This modification stabilizes the molecule against enzymatic degradation by dipeptidyl peptidase-4 (DPP-4), giving Tesamorelin a longer active half-life and more potent pituitary stimulation than native GHRH or Sermorelin.

The FDA approved Tesamorelin as Egrifta in 2010 specifically for reducing excess abdominal visceral fat in HIV-positive adults on antiretroviral therapy (ART). HIV lipodystrophy — characterized by central fat accumulation despite peripheral fat loss — is a major metabolic complication of long-term ART. Tesamorelin addresses this by restoring GH pulsatility and promoting visceral fat lipolysis.

Off-label, Tesamorelin has attracted interest from bodybuilders, biohackers, and anti-aging practitioners for its powerful visceral fat reduction, IGF-1 elevation, and potential cognitive benefits. Research also suggests Tesamorelin may improve cognition in mild cognitive impairment — a finding from National Institute on Aging-funded trials at Vanderbilt University.

Mechanism & Key Effects

🔬

GHRH Receptor Binding

Tesamorelin binds pituitary GHRH receptors with high affinity, triggering pulsatile GH secretion. The trans-3-hexenoic acid modification protects against DPP-4 cleavage — the primary metabolic enzyme

⚖️

Visceral Fat Lipolysis

GH stimulates hormone-sensitive lipase in visceral adipocytes, promoting lipolysis of visceral adipose tissue (VAT). Phase III trials demonstrated 15–20% reductions in VAT area by CT scan over 26 week

🔬

IGF-1 & Anabolism

Tesamorelin increases IGF-1 by 60–100% in clinical trials. Elevated IGF-1 drives anabolic effects including increased lean muscle mass, improved insulin sensitivity in muscle tissue, enhanced collagen

Cognitive Benefits

A Vanderbilt NIA-funded RCT found Tesamorelin improved executive function and verbal memory in older adults with mild cognitive impairment over 20 weeks. GH and IGF-1 both act on brain tissue — increa

Tesamorelin Dosing Protocol

Inject into abdominal subcutaneous tissue, rotating sites. Monitor IGF-1 at baseline and every 6 weeks. Target IGF-1: 200–350 ng/mL. Use Shotlee to track daily injections and body composition changes.

Side Effects & Considerations

⚠️

Common Side Effects

Injection site reactions: redness, bruising, pain (most common). Peripheral edema (fluid retention) — dose-dependent. Arthralgia (joint pain) — GH-mediated. Carpal tunnel symptoms at higher doses. Glu

🔬

Contraindications

Active malignancy (theoretical IGF-1 cancer concern). Diabetic retinopathy. Pregnancy or breastfeeding. Hypersensitivity to Tesamorelin or mannitol. Disrupted hypothalamic-pituitary axis

Вопросы по руководству

Это пептид, стимулирующий выработку собственного гормона роста, эффективно сжигающий висцеральный жир.

Препарат одобрен FDA для определенных состояний, но требует медицинского контроля уровня IGF-1 и сахара в крови.

Источники

  1. [1]Clinical TrialFalutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370.
  2. [2]Clinical TrialStanley TL et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389.
  3. [3]Clinical TrialBaker LD et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults. Arch Neurol. 2012;69(11):1420-1429.
  4. [4]FDAEgrifta (tesamorelin for injection). FDA Prescribing Information. Theratechnologies Inc. 2010.

Отслеживайте свой протокол Tesamorelin в Shotlee

Бесплатный журнал дозировок, отслеживание побочных эффектов и мониторинг показателей здоровья для вашего протокола.

🚀 Использовать Shotlee бесплатно